Chrysoula Margeti

Dr. Chrysoula Margeti

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2024 in Pets
Verified
Journal Article
Open access
PDF file
CMChrysoula Margeti
Chrysoula Margeti
CKCharalampos Kostakis
Charalampos Kostakis
VTVassiliki Tsioli
Vassiliki Tsioli
KKKonstantina Karagianni
Konstantina Karagianni
EFEUGENIA FLOURAKI
EUGENIA FLOURAKI
The use of multimodal anaesthesia and analgesia is desirable as part of a complete analgesic plan. Analgesic strategies for perioperative pain treatment include combinations of drugs with different means of action to increase their efficacy and to reduce the required doses and adverse effects. Local anaesthetics prevent the transduction and transmission of painful stimuli through their action on neuronal cell membranes. They undergo minimal systemic absorption and are therefore ideal alternatives to drugs that could result in systemic toxicity. Numerous benefits have been recognised for the use of local anaesthesia, such as a decreased need for systemic analgesics and decreased hospitalisation periods. Local anaesthetics have been used in veterinary medicine in several ways. Anatomical landmarks can be used to identify the target nerves and the clinician can employ an electrical nerve stimulator or ultrasound guidance to perform a more accurate injection. Local anaesthetic techniques can implement other drugs, apart from or in combination with local anaesthetics, such as opioids, α2−adrenergic agonists or vasoconstricting agents. This review article presents and discusses the most common techniques of local anaesthetic use in small animals, with the aim of providing the clinician with further and comprehensive information regarding the analgesic options during the perioperative period.

1 February 2024 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
PGPagona Gouletsou
Pagona Gouletsou
TZTheodora Zacharopoulou
Theodora Zacharopoulou
VSVassilis Skampardonis
Vassilis Skampardonis
Stefanos G GeorgiouStefanos G Georgiou
Stefanos G Georgiou
DDDimitrios Doukas
Dimitrios Doukas
VTVassiliki Tsioli
Vassiliki Tsioli
This study aimed to compare incisional wound healing in cats and dogs after the topical application of Μanuka honey and a new medical device, Dermapliq. Comparisons were made between each treatment and control, between the two treatments, and between dogs and cats. Twelve cats and twelve dogs were included in this study, and the impact of the two substances was examined through cosmetic, clinical, ultrasonographical, and histological evaluation. The use of Dermapliq in first-intention wound healing achieved a significantly better cosmetic evaluation score and better total clinical score at days 20–41, compared to the control, in both dogs and cats. The ultrasonographically estimated wound area was smaller with Dermapliq compared to the control. Wounds treated with Dermapliq showed histologically less inflammation compared to the control. The use of Manuka honey did not show a significantly better cosmetic score compared to the control. Skin thickening was significantly higher after using Manuka honey compared to the control and so was the total clinical score. However, the median wound area, as was evaluated ultrasonographically, was significantly smaller when wounds were treated with Manuka honey, the difference being more apparent in dogs. Dermapliq was proven to be a better choice in achieving favorable wound healing than Manuka honey in dogs and cats in first-intention healing. In our study, cats had a statistically better cosmetic score and less skin thickening and scar width compared to dogs. Histologically, cats showed significantly less edema, higher inflammation and angiogenesis scores, and lower fibroblast and epidermis thickening scores when compared to dogs.

5 December 2024 in Animals
Verified
Journal Article
Open access
PDF file
EFEUGENIA FLOURAKI
EUGENIA FLOURAKI
ELEpameinondas - Christos Loukopoulos
Epameinondas - Christos Loukopoulos
Dimitrios GougoulisDimitrios Gougoulis
Dimitrios Gougoulis
Ioannis SavvasIoannis Savvas
Ioannis Savvas
CMChrysoula Margeti
Chrysoula Margeti
VTVassiliki Tsioli
Vassiliki Tsioli
The administration of lidocaine as part of multimodal analgesia in dogs undergoing ovariohysterectomies demonstrates variable analgesic efficacy. The aim of this prospective, double–blinded clinical study was to evaluate the effectiveness of lidocaine 2% irrigation on the ovarian suspensory ligament, followed by localised massage, in achieving sufficient intraoperative analgesia. Thirty-eight female dogs were randomly divided to two groups and received either a splash block of 0.5 ml lidocaine 2% on each ovarian suspensory ligament (GL) or an equal volume of saline (GNS). All dogs were premedicated with dexmedetomidine (5 μg·kg−1) and buprenorphine (20 μg·kg−1) intramuscularly and meloxicam (0.2 mg·kg−1) subcutaneously. Anaesthesia was induced with propofol and maintained with isoflurane. The surgical procedure was initiated after an adequate depth of anaesthesia was achieved. Heart rate (HR), respiratory rate (fR) and mean arterial pressure (MAP) were continuously monitored. Fentanyl (2 μg·kg−1) was administered as rescue analgesia in case of a 30% increase in HR, fR, or MAP, compared to their values before manipulation of the ovaries. Data were analysed using a mixed model for repeated measures ANOVA and Pearson’s Chi-Square test. The need for rescue analgesia differed significantly between the two groups (p < 0.0005). In GNS, 89.47% (17/19) of the dogs required rescue analgesia, compared to 10.53% (2/19) of the dogs in GL. The relative risk of rescue for the GNS compared to the GL was approximately 8.5. In conclusion, intraoperative analgesia during ovariohysterectomies in dogs can be enhanced using a lidocaine 2% splash block combined with massage of the ovarian suspensory ligament.

22 March 2024 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
CMChrysoula Margeti
Chrysoula Margeti
GKGeorge Michel Kazakos
George Michel Kazakos
Apostolos D. GalatosApostolos D. Galatos
Apostolos D. Galatos
VSVassilis Skampardonis
Vassilis Skampardonis
TZTheodora Zacharopoulou
Theodora Zacharopoulou
EFEUGENIA FLOURAKI
EUGENIA FLOURAKI
The administered dose of dexmedetomidine may occasionally fail to produce the anticipated sedative effects. Therefore, a subsequent dose or administration of another sedative may enhance sedation; however, patient safety may be affected. The safety of seven different drugs administered at the following time point after an insufficient dose of dexmedetomidine was evaluated in a crossover, blind, experimental study that included six healthy adult cats. All cats received an initial dose of dexmedetomidine and a subsequent dose of either dexmedetomidine (Group DD), NS 0.9% (DC), tramadol (DT), butorphanol (DBT), buprenorphine (DBP), ketamine (DK), or midazolam (DM). Animal safety was assessed using repeated blood gas analysis and measurement of electrolytes, glucose, cardiac troponin I, and creatinine to evaluate cardiac, respiratory, and renal function. The median values of creatinine, cardiac troponin I, pH, partial pressure of carbon dioxide, potassium, and sodium did not change significantly throughout the study. Heart rate was significantly decreased in all groups after administration of the drug combinations, except for in the DK group. Respiratory rate decreased significantly after administration of the initial dose of dexmedetomidine and in the DBP and DM groups. The partial pressure of oxygen, although normal, decreased significantly after the administration of dexmedetomidine, whereas the median concentration of glucose increased significantly following the administration of dexmedetomidine. The results of our study suggest that the drug combinations used did not alter the blood parameters above normal limits, while cardiac and renal function were not compromised. Therefore, a safe level of sedation was achieved. However, the administration of dexmedetomidine reduced the partial pressure of oxygen; thus, oxygen supplementation during sedation may be advantageous. Additionally, the increase in glucose concentration indicates that dexmedetomidine should not be used in cats with hyperglycaemia, whereas the decrease in haematocrit suggests that dexmedetomidine is not recommended in anaemic cats.

25 April 2024 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
CMChrysoula Margeti
Chrysoula Margeti
GKGeorge Michel Kazakos
George Michel Kazakos
VSVassilis Skampardonis
Vassilis Skampardonis
Apostolos D. GalatosApostolos D. Galatos
Apostolos D. Galatos
TZTheodora Zacharopoulou
Theodora Zacharopoulou
EFEUGENIA FLOURAKI
EUGENIA FLOURAKI
Dexmedetomidine is an a2-agonist commonly used in veterinary practice. Occasionally, the administered dose of dexmedetomidine may result in insufficient sedation, and an additional dose or drug may be required. The sedative effects of seven different drugs administered at subsequent time points after an initial, insufficient dose of dexmedetomidine were evaluated. Seven adult cats participated in this crossover, blind, randomised study. The groups consisted of two consecutive doses of dexmedetomidine (15 + 10 μg/kg) (DD) or a dose of dexmedetomidine (15 μg/kg) followed by either NS 0.9% (DC-control group), tramadol 2 mg/kg (DT), butorphanol 0.2 mg/kg (DBT), buprenorphine 20 μg/kg (DBP), ketamine 2 mg/kg (DK), or midazolam 0.1 mg/kg (DM). Sedation was evaluated using the Grint sedation scale. In all groups, atipamezole was administered at the end of the evaluation, and recovery was assessed using the Lozano and Sams recovery scales. The DC and DM groups exhibited minimal sedative effects. The maximum sedative effect was observed in the DD and DK groups, while sedation in the DD and DK groups was significantly higher compared to the DC group. Recovery in all groups was uneventful, except in the DM group, where it was prolonged and difficult, although no statistically significant difference was detected. Therefore, insufficient sedation with dexmedetomidine can be enhanced by a subsequent dose of dexmedetomidine, ketamine, or butorphanol, whereas the addition of midazolam reduces sedation and prolongs recovery.

11 June 2026 in Pets
Verified
Journal Article
Open access
PDF file
TZTHEODORA ZACHAROPOULOU
THEODORA ZACHAROPOULOU
PGPagona Gouletsou
Pagona Gouletsou
VSVassilis Skampardonis
Vassilis Skampardonis
Stefanos G GeorgiouStefanos G Georgiou
Stefanos G Georgiou
DDDimitrios Doukas
Dimitrios Doukas
VTVassiliki Tsioli
Vassiliki Tsioli
Skin wounds in dogs and cats are frequently managed by second-intention healing, yet comparative evidence on topical treatments in these species remains limited. This study investigated wound-healing dynamics in dogs and cats using a standardized experimental model that enabled direct interspecies and within-animal comparison of treatment responses during secondary-intention healing. Standardized full-thickness cutaneous wounds were created on the dorsolateral trunk, with multiple wounds per animal randomly assigned to different treatments, including Manuka honey, Dermapliq, and untreated controls. Healing was evaluated using a multimodal approach, including clinical endpoints, planimetric analysis of epithelialization, contraction and total healing, ultrasonographic assessment, and blinded histopathology. Planimetry-derived total wound healing, the primary endpoint, did not differ significantly among treatments, while treatment-associated differences were identified in selected secondary endpoints. Dermapliq-treated wounds reached complete epithelial coverage earlier and showed smaller ultrasonographic wound areas than untreated controls, whereas Manuka honey was associated with faster complete granulation coverage but greater exudate quantity. Interspecies differences were also identified, with cats generally exhibiting slower progression to key healing endpoints than dogs under identical experimental conditions. These findings suggest species-specific healing responses and phase-dependent treatment-associated differences during secondary-intention wound healing in a controlled experimental model. However, they should not be interpreted as evidence of broad treatment superiority. Further studies in naturally occurring, larger, contaminated, infected, or chronic wounds are required before direct clinical extrapolation.